|Bid||3,335.00 x 0|
|Ask||3,355.00 x 0|
|Day's Range||3,320.00 - 3,395.00|
|52 Week Range||2,342.00 - 3,425.00|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||28.54|
|Earnings Date||Apr 30, 2021|
|Forward Dividend & Yield||38.00 (1.29%)|
|Ex-Dividend Date||Sep 29, 2021|
|1y Target Est||N/A|
They say March comes in like a lion and goes out like a lamb. For the markets, it’s looking like it’s coming in as a bull. But the bull is getting a bit erratic given the big move in fuel prices and the wild action in the bond market recently. The U.S. dollar index is near its 52-week lows, and that means rates on bonds have risen significantly. That’s going to change the real estate market, and that will have spillover effects in portfolio holdings. We’ve also already seen Big Tech get hit with selling. Plus, the Federal Reserve has said it will not intervene at this point and isn’t worried about inflation, so investors will start to make different decisions in this environment.InvestorPlace - Stock Market News, Stock Advice & Trading Tips What it means for the individual investor is that it’s time to weed out the weak and vulnerable from your portfolio now. 8 Stocks to Buy for March These seven stocks to sell for March are a very good start: Biogen (NASDAQ:BIIB) Boston Scientific (NYSE:BSX) Duke Energy (NYSE:DUK) GlaxoSmithKline (NYSE:GSK) Las Vegas Sands (NYSE:LVS) Raytheon (NYSE:RTX) AT&T (NYSE:T) Stocks to Sell for March: Biogen (BIIB) Source: Pavel Kapysh / Shutterstock.com A couple weeks ago, a slew of drug companies announced earnings. All showed strong Q4 earnings and revenue. But BIIB came in mixed, with weak earnings but good revenue. But looking back isn’t what the markets or the analysts really care about. The markets are forward-looking. And BIIB’s guidance wasn’t very optimistic. As a leader in neurological and neurodegenerative diseases, it wasn’t a part of the wild ride some companies had in the race to a vaccine. But even that hype has left the market, so weak guidance in a wild market like this is going to get your stock punished. There’s no point holding and hoping when there could be more downside to come, as sector rotation is sure to be the story of the next few months. This is the prime reason Biogen made the list of stocks to sell for March. BIIB is up 11.6% year-to-date, yet in the past 12 months it’s still in the red, down 15.7%. Boston Scientific (BSX) Source: Pavel Kapysh / Shutterstock.com In late January, BSX announced that it was buying a leader in the ambulatory cardiography space, Preventice Solutions, for $925 million. It already owns a 22% stake, so when all is said and done, the deal will cost around $720 million. And while the space for implantable cardiac monitoring equipment is growing a good clip, it’s a $2 billion market, and BSX already had a nice piece of that market with its own equipment as well as its investment in Preventice. But even with that news and some new buy recommendations from analysts, the stock has been treading water for the past 12 months. 8 Risky Stocks to Buy If Danger Is Your Middle Name Granted, it’s a major medical-device manufacturer that sells more than 13,000 products in 100-plus countries. But this isn’t the kind of stock that’s going to make much of a move any time soon. Duke Energy (DUK) Source: jadimages / Shutterstock.com You would think if there were any energy company stocks to sell in March, it would be Texas-based utilities. But we’re not here to state the obvious, and that cow has already left the barn. I want you to pick stocks that you might not otherwise think are in trouble. DUK is a major East Coast utility with operations in the Carolinas, Ohio, Kentucky and Puerto Rico. It has natural gas distribution operations in a few other states as well. It’s an old school utility that has been a leader in clean energy, but it also sits in the heart of coal country and has some legacy issues to deal with in converting to cleaner operations. Last year, there was talk of another big renewable energy company looking to buy DUK, but nothing came of that. Although, that remains a possibility for some of these utilities that have soared in the past year. DUK’s recent earnings were mixed, and revenue was down year-over-year, largely due to the fact that its commercial and industrial customers were hamstrung by the pandemic. The stock is down 9% in the past three months and still trades at a price-to-earnings (P/E) ratio of 51.7, which is massive for a utility. Overpriced and underperforming is not a good combination, making this an easy pick for this list of stocks to sell for March. GlaxoSmithKline (GSK) Source: Willy Barton / Shutterstock.com With a market capitalization of $84 billion, GSK is certainly in the Big Pharma club. Like many of its peers, it jumped into the vaccine race, but its initial vaccine had a lowered effectiveness in the elderly, and that pushed its development back a few steps. It’s now revamping its position with a new joint venture, and it has another to develop a vaccine for the Covid-19 variants that are popping up around the world. But GSK is doing a lot more than vaccine work. Some of its drugs have become go-to antibiotics, cancer treatments and HIV/AIDs drugs, and it even developed the first vaccine for malaria. 7 Safe Stocks to Buy for Your Retirement That hasn’t helped the stock, however. In the past month, the stock is down 13.5%, and it’s down nearly 179% in the past 52 weeks. Its 6.1% dividend won’t put a dent in those numbers. Las Vegas Sands (LVS) Source: Andy Borysowski / Shutterstock.com If you have ever been to Las Vegas, you know how massive the properties are out there. On the big, flat desert, they lose their scale until you go inside and realize how massive these structures are. Just to keep them running costs huge sums. So, when they sit nearly dormant for months on end, keeping the lights on is a real challenge. LVS only has two resorts in Vegas at this point, but it has built a large number in Macau and Singapore. But during the pandemic these operations were also affected. And recently the high-profile CEO and founder Sheldon Adelson died. While management has been well established, a shift in leadership always brings some kind of change. The sector has been doing well as pandemic numbers improve, but the economy is going to have to improve along with it, and we’re still weeks away from a new stimulus deal. Your best bet here is to count LVS as one of the stocks to sell for March. Raytheon (RTX) Source: JHVEPhoto / Shutterstock.com It’s hard to believe that a defense company would make a list of stocks to sell for March. The defense sector is one of the most consistently funded departments in the government. And budgets have been rising year after year. But the U.S. has now reached a point of significant debt, as deficit spending has gone through the roof in recent years. Add in the multi-trillion-dollar stimulus packages for the pandemic, and the numbers have gone parabolic. That means cuts will have to come from somewhere, and the biggest pot of money is in defense. RTX and its peers aren’t going to starve. But they’re not going to thrive, either. Even our adversaries are struggling economically, so the thought of significant military engagements aren’t too concerning in the near future. 7 Dividend Stocks Offering Little More Than Danger What’s more, its Pratt and Whitney aircraft engine division may have some troubles after the recent incidents with their engines coming apart in-flight. The risks outweigh the opportunities here. AT&T (T) Source: Roman Tiraspolsky / Shutterstock.com For months now, I’ve been ringing the alarm on this stock. Yes, this major telecom company is delivering a tantalizing 7.1% dividend, but the stock is down 24% in the past 12 months. The math is pretty easy, and it doesn’t work out in investors’ favor. Some will argue that it’s one of America’s most iconic brands and that it will endure as it has for decades. But there are many iconic brands that are mere shadows of themselves because they thought they were bigger than the markets and had such power that they could weather any storm. We are living in a very disruptive age, and any sense of comfort derived from a legacy brand can be dangerous. Innovation has always been the hallmark of telecom companies. Even At&T understood the value of its Bell Labs, at least until 1996 when it spun it off. The danger for AT&T is that it’s no longer an innovator. And investors are picking up on this. It’s still a massive company and isn’t going to disappear, but it shouldn’t be a big investment. On the date of publication, Louis Navellier had no positions in any of the stocks in this article. Louis Navellier did not have (either directly or indirectly) any other positions in the securities mentioned in this article. The InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article. Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system — with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the “Master Key” to profiting from the biggest tech revolution of this (or any) generation. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next Potential Winner It doesn’t matter if you have $500 in savings or $5 million. Do this now. #1 Play to Profit from Biden's Presidency The post 7 Stocks to Sell for March appeared first on InvestorPlace.
Biotech company AC Immune said Thursday its Alzheimer's vaccine generated key antibodies in the brain, leading ACIU stock to pop. Shares hit a three-year high in premarket action.
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the expiration date results of its previously announced offer to purchase for cash (the “Cash Offer”) its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion in aggregate principal amount, on the terms and subject to the conditions set forth in the Offer to Purchase dated February 4, 2021 (the “Offer to Purchase”) and the accompanying certification of eligibility to participate in the Cash Offer, the instructions for such certification and the notice of guaranteed delivery (collectively, the “Cash Offer Documents”). The Cash Offer expired at 5:00 p.m., New York City time, on February 10, 2021 (the “Expiration Date”). The “Settlement Date” will be promptly following the Expiration Date and is expected to be February 16, 2021. The following table sets forth the aggregate principal amount of Notes validly tendered and not validly withdrawn at or prior to the Expiration Date, including the aggregate principal amount tendered pursuant to the guaranteed delivery procedures described in the Offer to Purchase at or prior to the Expiration Date, which Biogen expects to accept on the Settlement Date in connection with the Cash Offer. Title of Notes to be ExchangedPrincipal Amount Outstanding as of the Expiration DateCUSIP/ISINPrincipal Amount of Notes Tendered as of the Expiration Date for Purchase(1)Principal Amount of Notes Tendered Pursuant to Guaranteed Delivery Procedures5.200% Senior Notes due 2045$1,750,000,00009062X AD5 / US09062XAD57$8,907,000$2,864,000 (1) Excluding Notes tendered pursuant to guaranteed delivery procedures. These amounts are based on information provided by the tender agent as of the Expiration Date. Upon the terms and subject to the conditions set forth in the Cash Offer Documents, on the Settlement Date, Eligible Holders (as defined below) who (i) validly tendered and did not validly withdraw Notes at or prior to the Expiration Date or (ii) delivered a valid notice of guaranteed delivery and all other required documents at or prior to the Expiration Date and tender their Notes at or prior to 5:00 p.m., New York City time, on February 12, 2021 (the “Guaranteed Delivery Date”), pursuant to certain guaranteed delivery procedures, and whose Notes are accepted for purchase by Biogen, will receive the Tender Consideration (as defined in the Offer to Purchase), as well as accrued and unpaid interest on such Old Notes from the last interest payment date to, but excluding, the Settlement Date. Based on the foregoing tenders, Biogen expects to pay in cash Tender Consideration of approximately $16 million in the aggregate, assuming that all Notes tendered pursuant to the guaranteed delivery procedures will be tendered at or prior to the Guaranteed Delivery Date. The actual aggregate amount of cash that will be paid on the Settlement Date is subject to change based on deliveries under the guaranteed delivery procedures and final validation of tenders. Biogen will deliver cash as payment for Notes accepted for purchase in the Cash Offer on the Settlement Date. Interest on the Notes accepted for purchase in the Cash Offer, including those tendered pursuant to the guaranteed delivery procedures, will cease to accrue on the Settlement Date. Biogen also announced today the expiration date results of its separate exchange offer (the “Exchange Offer”), made only to Ineligible Holders (as defined below), to exchange Notes for a new series of senior notes and cash. The complete terms and conditions of the Cash Offer are set forth in the Cash Offer Documents, which were distributed to Eligible Holders in connection with the Cash Offer. The conditions to the Cash Offer have been satisfied as of the Expiration Date. The Cash Offer was made only to “Eligible Holders,” which are holders of Notes that certified that they are not “qualified institutional buyers”, as that term is defined in Rule 144A under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and that are not non-U.S. persons, as that term is defined in Rule 902 under the Securities Act, located outside of the U.S. within the meaning of Regulation S under the Securities Act (unless they are “retail investors” in the European Economic Area or in the United Kingdom, or investors in any province or territory of Canada that are individuals or that are institutions or other entities that do not qualify as both “accredited investors” and “permitted clients”), as more fully described in the Offer to Purchase. All holders of Notes who are not Eligible Holders are “Ineligible Holders”. Only Eligible Holders who submitted a valid eligibility certificate were authorized to participate in the Cash Offer. Global Bondholder Services Corporation is serving as the tender agent and information agent for the Cash Offer. Questions or requests for assistance related to the Cash Offer may be directed to Global Bondholder Services Corporation (866) 470-3900 (U.S. toll-free) or (212) 430-3774 (collect for banks and brokers), or via e-mail at email@example.com. You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Cash Offer. This news release is not an offer to buy or a solicitation of an offer to sell any of the securities described herein. The Cash Offer was made solely by the Cash Offer Documents and only to such persons and in such jurisdictions as was permitted under applicable law and the terms and conditions of the Cash Offer. About Biogen At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain. Biogen Safe Harbor This news release contains forward-looking statements, including statements relating to the anticipated Settlement Date, the potential consummation of the Cash Offer and the Exchange Offer, and the aggregate amount of cash that will be paid on the Settlement Date. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would” and other words and terms of similar meaning. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including the risk that the Exchange Offer is not consummated, the risk that the Cash Offer will not be consummated on the terms and conditions set forth in the Cash Offer Documents or at all, the risk that the Settlement Date may be delayed, the risk that the aggregate amount of cash that will be paid on the Settlement Date may change, the risk that the Cash Offer may be adversely affected by market conditions or adverse changes to our business or prospects and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on current beliefs and expectations and speak only as of the date of this news release. We do not undertake any obligation to publicly update any forward-looking statements. Biogen Media Contact:Biogen Investor Contact:David CaouetteMike HenckeBiogen Inc.Biogen Inc.Tel: (781) 464-3260Tel: (781) 464-2442